abeonatherapeutics.com (ABEO) Long-Term Liabilities to Equity

The Abeona Therapeutics (ABEO) price chart reflects a debt-to-equity ratio of 0.04. Abeona Therapeutics relies on its pricing power for cell products following FDA approval. The business's success is based on the scientists' dedication to the idea of curing children. The technology stack centers on the implementation of AI models and automated bioreactors, which eliminates human error in the creation of gene therapies.

This ratio determines the share of long-term liabilities within the equity structure, measuring the business's degree of financial autonomy and debt load over a horizon exceeding one year. By analyzing the long-term debt-to-equity valuation, an investor can understand the extent to which the development of gene therapy at Abeona Therapeutics (ABEO) is funded by borrowed capital, which is critical for the capital-intensive clinical development of innovative treatment methods.